Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Novavax's 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3Upon regulatory approval,...

Related Keywords

India ,Ali Chartan ,Filip Dubovsky ,Erika Schultz ,Vaccine Administration Errors ,Centers For Disease ,Vaccination Program ,European Centers For Disease ,Prnewswire Novavax Inc ,Nasdaq ,Exchange Commission ,European Union ,Novavax Inc ,Linkedin ,Centers For Disease Control ,Emergency Use Authorization ,Coronavirus Disease ,Acute Allergic Reactions ,Disease Control ,Vaccine Effectiveness ,Adverse Events ,Vaccine Administration ,Vaccine Adverse Event Reporting System ,Multisystem Inflammatory Syndrome ,Fax Number ,Telephone Number ,Adjuvanted Fact Sheet ,Healthcare Providers Administering Vaccine ,Vaccination Providers ,Financial Condition ,Annual Report ,Quarterly Reports ,Variant Proportions ,Nat Rev ,Markets ,